Akebia Therapeutics Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Akebia Therapeutics stock.
View analyst ratings for Akebia Therapeutics or view top-rated stocks.

Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akebia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Akebia Therapeutics.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.12. The biopharmaceutical company had revenue of $52.30 million for the quarter, compared to analysts' expectations of $43.80 million. Akebia Therapeutics had a negative net margin of 151.39% and a negative trailing twelve-month return on equity of 96.29%.
View Akebia Therapeutics' earnings history.

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AKBA shares have decreased by 47.6% and is now trading at $3.64.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued 12-month price targets for Akebia Therapeutics' shares. Their forecasts range from $3.00 to $18.00. On average, they expect Akebia Therapeutics' share price to reach $7.83 in the next year. This suggests a possible upside of 115.2% from the stock's current price.
View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts.

28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Akebia Therapeutics include Zentalis Pharmaceuticals (ZNTL), Morphic (MORF), Xencor (XNCR), Revance Therapeutics (RVNC), Myovant Sciences (MYOV), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Prothena (PRTA), Atea Pharmaceuticals (AVIR), Amarin (AMRN), Organogenesis (ORGO), Ironwood Pharmaceuticals (IRWD), Seres Therapeutics (MCRB), Centessa Pharmaceuticals (CNTA) and Harmony Biosciences (HRMY).
View all of AKBA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.74%), Nantahala Capital Management LLC (3.22%), Morgan Stanley (2.09%), Goldman Sachs Group Inc. (1.74%), Geode Capital Management LLC (1.63%) and Dimensional Fund Advisors LP (1.52%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics.

AKBA stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, JPMorgan Chase & Co., Goldman Sachs Group Inc., Credit Suisse AG, Renaissance Technologies LLC, Squarepoint Ops LLC, AQR Capital Management LLC, and Man Group plc. Company insiders that have sold Akebia Therapeutics company stock in the last year include John P Butler, Michel Dahan, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics or view top insider-selling stocks.

AKBA stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Citigroup Inc., BlackRock Inc., Dimensional Fund Advisors LP, Rafferty Asset Management LLC, PDT Partners LLC, Mirabella Financial Services LLP, and Geode Capital Management LLC. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics or or view top insider-buying stocks.

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKBA stock can currently be purchased for approximately $3.64.

Akebia Therapeutics has a market capitalization of $582.82 million and generates $295.31 million in revenue each year. The biopharmaceutical company earns $-383,460,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

Akebia Therapeutics employs 379 workers across the globe.

The official website for Akebia Therapeutics is www.akebia.com.

Akebia Therapeutics is headquartered at 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]